National Health Institute Carlos III, Spain
We are experts in the development of preclinical glioma models, working with patient-derived cells as 3D spheres or xenografts, where test the efficiency of different therapeutic drugs. We have characterized the behaviour of these lines in the mouse brain, from the most invasive ones to the most angiogenic and necrotic tumors. We are also very interested in allogenic and immunocompetent models, to analyse the participation of the tumor microenvironment in the response to chemotherapy (both as a physical barrier and as protective cells).
Existing collaborations relevant to drug delivery
Collaboration with Dr.Marcos García-Fuentes (Universidad de Santiago, Spain) and Alexander Cameron (University of Nottingham, UK) for the development of novel polymers for gene therapy in gliomas.
Collaboration with Dr. Angel Ayuso (Hospitales de Madrid, Spain) for the characterization of the different behaviors of glioma cell lines.
Collaboration with Dr. Ochoa and Dr. Fernandez (Universidad de Zaragoza) on the usage of microfluidic devices to test anti-glioma compounds in a more biological setting.
Publications relevant to drug delivery
Sepúlveda-Sánchez JM, Vaz MA, Balañá C, Gil-Gil M, Reynés G, et al (2017) Phase II trial of dacomitinib, a pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor, in recurrent GB patients with EGFR amplification. (2017) Neuro-Oncol.
Ayuso JM, Monge R, Martínez-González A, Virumbrales-Muñoz M, Llamazares GA, et al. Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events. (2016) Neuro-Oncol., 19(4):503-513
García-Romero N, González-Tejedo C, Carrión-Navarro J, Esteban-Rubio S, Rackov G, et al. (2016) Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after in vitro passaging in serum-free media. Oncotarget, (40):65888-65901.
Zahonero C, Aguilera P, Ramírez-Castillejo C, Pajares M, Bolós MV, et al. (2015) Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol. Can.Ther. 14 (7): 1548-1558
González-Gómez P, Crecente-Campo J, Zahonero C, de la Fuente M, Hernández-Laín A, et al. (2015) Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma. Oncotarget, 6 (13): 10950-10963
Email for contact details